Cart
sales@molnova.com
Cilengitide trifluoroacetate
CAS No. 199807-35-7
Cilengitide trifluoroacetate( EMD 121974 | NSC 707544 )
Catalog No. M19460 CAS No. 199807-35-7
Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCilengitide trifluoroacetate
-
NoteResearch use only, not for human use.
-
Brief DescriptionCilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
-
DescriptionCilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
-
In Vitro——
-
In Vivo——
-
SynonymsEMD 121974 | NSC 707544
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
Recptorαvβ3 receptor |αvβ5 receptor
-
Research AreaCancer
-
IndicationGlioblastoma; Head and neck Cancer; Lymphoma; Non-small cell lung Cancer; Prostate Cancer; Solid tumours
Chemical Information
-
CAS Number199807-35-7
-
Formula Weight702.68
-
Molecular FormulaC29H41F3N8O9
-
Purity>98% (HPLC)
-
SolubilityDMSO:93 mg/mL (132.4 mM);Ethanol:<1 mg/mL;Water:8 mg/mL (11.38 mM)
-
SMILESOC(=O)C(F)(F)F.CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Echistatin, α1 isofo...
Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) receptors (IC50 = 30 nM) in vitro.
-
Natalizumab
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
-
Fibronectin CS1 Pept...
he connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. CS1 peptide of fibronectin, which lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models. The use of Fibronectin CS1 Peptide might offer a promising therapeutic approach for combating and preventing cancer metastasis.
